Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Lundbeck

Market Cap 40.56B 6.29B 5.43B 4.99B 4.7B 8.82B 594B 8.9B 59.13B 23.02B 291B 23.61B 23.11B 1,008B P/E 2026 *
9.36x
P/E 2027 * 9.15x
Enterprise Value 44.66B 6.93B 5.98B 5.49B 5.17B 9.72B 654B 9.8B 65.1B 25.35B 321B 26B 25.44B 1,110B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.57x
Free-Float
30.76%
Yield 2026 *
3.5%
Yield 2027 * 3.58%
1 day-0.42%
1 week-3.11%
Current month-2.58%
1 month+2.43%
3 months+4.52%
6 months+2.43%
Current year-0.97%
1 week 35.65
Extreme 35.65
37.3
1 month 34.75
Extreme 34.75
37.55
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 66 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%-3.11% - - 6.3B
-0.88%-1.70%+7.26%+89.36% 91.96B
+0.18%+5.29%+38.11%+149.62% 53.33B
0.00%-3.77%-13.27%+230.59% 22.86B
-0.25%-0.06%-9.70%-25.86% 8.06B
-1.98%-0.72%-36.58%-34.41% 7.33B
-0.77%-0.30%-8.68%-35.11% 6.76B
-0.18%-0.59%-1.63%+18.54% 5.31B
-0.63%0.00%-10.53%-14.83% 3.53B
-0.96%-1.45%+9.00%+9.58% 3.34B
Average -0.60%-0.08%-2.89%+43.05% 22.5B
Weighted average by Cap. -0.50%+1.34%+9.76%+102.96%

Financials

2026 *2027 *
Net sales 25.7B 3.99B 3.44B 3.16B 2.98B 5.59B 376B 5.64B 37.47B 14.59B 185B 14.96B 14.64B 639B 25.74B 3.99B 3.44B 3.17B 2.98B 5.6B 377B 5.65B 37.52B 14.61B 185B 14.98B 14.66B 640B
Net income 4.71B 731M 630M 579M 545M 1.02B 68.95B 1.03B 6.87B 2.67B 33.84B 2.74B 2.68B 117B 4.81B 746M 643M 591M 557M 1.05B 70.36B 1.05B 7.01B 2.73B 34.53B 2.8B 2.74B 119B
Net Debt 4.1B 636M 548M 504M 474M 892M 59.98B 899M 5.97B 2.33B 29.44B 2.39B 2.33B 102B -30.08M -4.66M -4.02M -3.7M -3.48M -6.54M -440M -6.6M -43.85M -17.07M -216M -17.51M -17.13M -747M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
26-06-17 35.85 kr -0.14% 22,894
26-06-16 35.90 kr -1.78% 56,002
26-06-15 36.55 kr 0.00% 62,560
26-06-12 36.55 kr -1.48% 54,355
26-06-11 37.10 kr +0.27% 39,971
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.18DKK
Average target price
47.21DKK
Spread / Average Target
+11.92%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!